Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial
AW See, P Conway, M Frydenberg… - … Journal of Cancer, 2024 - Wiley Online Library
Metastasis‐directed therapy (MDT) for oligometastatic prostate cancer (PCa), including
stereotactic body radiotherapy (SBRT), has shown promise but is still considered …
stereotactic body radiotherapy (SBRT), has shown promise but is still considered …
[HTML][HTML] Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells
KR Parajuli, Y Jung, RS Taichman - Oncology Reports, 2024 - spandidos-publications.com
Prostate cancer (PCa) is one the most common malignancies in men. The high incidence of
bone metastasis years after primary therapy suggests that disseminated tumor cells must …
bone metastasis years after primary therapy suggests that disseminated tumor cells must …
Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting
M Wenzel, B Hoeh, N Wagner, F Koll… - Journal of the …, 2024 - Wiley Online Library
Background The landscape of systemic therapies for metastatic hormone‐sensitive
(mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the …
(mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the …
Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
Y Wei, R Zhang, D Zhong, Z Chen, G Chen… - Frontiers in …, 2023 - frontiersin.org
Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa)
remains uncertain. The primary endpoints of previous retrospective and phase II clinical …
remains uncertain. The primary endpoints of previous retrospective and phase II clinical …
[HTML][HTML] Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First-to Sixth-line Metastatic Castration …
M Wenzel, C Siech, B Hoeh, F Koll, C Humke… - European Urology Open …, 2024 - Elsevier
Background and objective With approval of novel systemic therapies within the past decade
for metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate …
for metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate …
Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone‐sensitive prostate cancer
J Gong, JL Janes, C Trustram Eve, S Stock, J Waller… - Cancer, 2024 - Wiley Online Library
Background This study was conducted to better characterize the epidemiology, clinical
outcomes, and current treatment patterns of de novo oligometastatic hormone‐sensitive …
outcomes, and current treatment patterns of de novo oligometastatic hormone‐sensitive …